SCHEMBL15525575

SCHEMBL15525575

CS(=O)(=O)c1sc2nc(-c3cccs3)cc(-c3ccccc3)c2c1N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 19/20 1.00
KDM4E B2RXH2 4/20 1.00
ALDH1A1 P00352 4/20 1.00
MAPT P10636 4/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
NPSR1 Q6W5P4 2/20 1.00
POLB P06746 1/20 1.00
ALOX15 P16050 1/20 1.00
TSHR P16473 1/20 1.00
MAPK1 P28482 1/20 1.00
CASP1 P29466 1/20 1.00
CASP7 P55210 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
HSD17B10 Q99714 1/20 1.00
RXFP1 Q9HBX9 1/20 1.00
TLR9 Q9NR96 1/20 0.78
L3MBTL1 Q9Y468 1/20 0.64
HTR1A P08908 1/20 0.60
HTR2A P28223 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15525561 0.84 HPGD (1.00) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL21973488 0.84 HPGD (0.94) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL18165749 0.84 HPGD (0.72) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL21974107 0.83 HPGD (0.93) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL23657607 0.83 HPGD (1.00) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL18153497 0.82 HPGD (0.70) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL22777185 0.82 HPGD (0.75) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL22939512 0.81 HPGD (0.69) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL19983451 0.81 HPGD (0.67) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL18962635 0.81 HPGD (0.67) HPGDKDM4EALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043443-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY UNIV CASE WESTERN RESERVE (US) 2024-02-08 US disclosed
US-20230355636-A1 COMBINATIONS OF 15-PGDH INHIBITORS WITH CORTICOSTEROIDS AND/OR TNF INHIBITORS AND USES THEREOF UNIV CASE WESTERN RESERVE (US) 2023-11-09 US disclosed
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity UNIV TEXAS (US) 2023-09-14 US disclosed
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity UNIV TEXAS (US) 2023-09-14 US disclosed
US-11690847-B2 Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2023-07-04 US disclosed
US-11690847-B2 Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2023-07-04 US disclosed
US-20230165883-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING CORONARY DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-06-01 US disclosed
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-11426420-B2 Inhibitors of short-chain dehydrogenase activity for treating coronary disorders CASE WESTERN RESERVE UNIVERSITY (US) 2022-08-30 US disclosed
US-20170165241-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-15 US disclosed
US-20170165241-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-15 US disclosed
WO-2016144958-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY (US) 2016-09-15 WO disclosed
WO-2015065716-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2015-05-07 WO disclosed
US-20150072998-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-03-12 US disclosed
US-20150072998-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-03-12 US disclosed
US-20150072998-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-03-12 US disclosed
EP-2838533-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY Case Western Reserve University (US) 2015-02-25 EP disclosed
WO-2013158649-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2013-10-24 WO disclosed
WO-2013158649-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2013-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS HPGD 1/4885KDM4E 3506/4885ALDH1A1 126/4885
US-20170165241-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY PTGS1, HPGD, PTGIS HPGD 2/4885KDM4E 3434/4885ALDH1A1 415/4885
US-20230165883-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING CORONARY DISORDERS GCDH, HPGD, PGD HPGD 2/4885KDM4E 3034/4885ALDH1A1 118/4885
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity HPGD, GCDH, HPGDS HPGD 1/4885KDM4E 3506/4885ALDH1A1 126/4885
US-20230355636-A1 COMBINATIONS OF 15-PGDH INHIBITORS WITH CORTICOSTEROIDS AND/OR TNF INHIBITORS AND USES THEREOF HPGD, HPGDS, PTGS1 HPGD 1/4885KDM4E 4127/4885ALDH1A1 842/4885
US-11426420-B2 Inhibitors of short-chain dehydrogenase activity for treating coronary disorders GCDH, HPGD, PGD HPGD 2/4885KDM4E 3034/4885ALDH1A1 118/4885
US-11690847-B2 Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof HPGD, HPGDS, PTGS1 HPGD 1/4885KDM4E 4259/4885ALDH1A1 972/4885
US-20240043443-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY PTGS1, HPGD, PTGIS HPGD 2/4885KDM4E 3434/4885ALDH1A1 415/4885
US-20150072998-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY PTGS1, HPGD, PTGIS HPGD 2/4885KDM4E 3434/4885ALDH1A1 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.